Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$33.64 +0.5%	$30.58	$23.95 ▼ $52.34	$5.35B	0.15	1.57 million shs	1.65 million shs
LEGN Legend Biotech	$28.75 -0.8%	$31.91	$27.34 ▼ $60.87	$5.28B	0.2	1.30 million shs	2.15 million shs
NUVL Nuvalent	$73.63 -1.5%	$71.01	$55.54 ▼ $113.51	$5.27B	1.42	492,833 shs	532,918 shs
SRRA Sierra Oncology	$54.99	$54.93	$14.91 ▼ $55.19	$1.34B	0.03	931,731 shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	+3.18%	+0.60%	+12.24%	+0.81%	-8.20%
LEGN Legend Biotech	+2.40%	-0.28%	-15.86%	-17.25%	-31.15%
NUVL Nuvalent	+4.66%	+2.09%	-1.46%	-0.29%	+13.20%
SRRA Sierra Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IONS Ionis Pharmaceuticals	4.3932 of 5 stars	4.3	1.0	0.0	3.0	3.5	3.3	0.6
LEGN Legend Biotech	3.3019 of 5 stars	4.5	2.0	0.0	0.0	3.4	1.7	0.6
NUVL Nuvalent	2.5105 of 5 stars	3.5	2.0	0.0	0.0	3.0	3.3	0.0
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.65	Moderate Buy	$56.67	68.45% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	165.04% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	56.87% Upside
SRRA Sierra Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SRRA, LEGN, NUVL, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/14/2025	LEGN Legend Biotech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$88.00 ➝ $71.00
5/14/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00
5/1/2025	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00
5/1/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $50.00
4/30/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
4/22/2025	LEGN Legend Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/15/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$717.25M	7.46	N/A	N/A	$3.70 per share	9.09
LEGN Legend Biotech	$728.30M	7.25	N/A	N/A	$6.88 per share	4.18
NUVL Nuvalent	N/A	N/A	N/A	N/A	$10.94 per share	N/A
SRRA Sierra Oncology	$300K	4,476.00	N/A	N/A	$6.16 per share	8.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	8/7/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.59	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	8/8/2025 (Estimated)
NUVL Nuvalent	-$126.22M	-$4.39	N/A	N/A	N/A	N/A	-28.63%	-27.15%	8/14/2025 (Estimated)
SRRA Sierra Oncology	-$94.66M	-$6.77	N/A	N/A	N/A	N/A	-111.88%	-100.01%	N/A

Latest SRRA, LEGN, NUVL, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
LEGN Legend Biotech	0.27	4.98	4.90
NUVL Nuvalent	N/A	23.07	23.07
SRRA Sierra Oncology	0.02	21.27	21.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
LEGN Legend Biotech	70.89%
NUVL Nuvalent	97.26%
SRRA Sierra Oncology	99.30%

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	2.60%
LEGN Legend Biotech	0.02%
NUVL Nuvalent	12.52%
SRRA Sierra Oncology	44.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable
LEGN Legend Biotech	1,070	183.76 million	182.60 million	Optionable
NUVL Nuvalent	40	71.60 million	62.16 million	Optionable
SRRA Sierra Oncology	109	24.42 million	13.65 million	Optionable

SRRA, LEGN, NUVL, and IONS Headlines

Recent News About These Companies

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

October 4, 2024 | pharmaphorum.com

New cancer treatment center breaks ground in Redding

September 25, 2024 | actionnewsnow.com

Implementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community Hospital

September 19, 2024 | ascopubs.org

New regional cancer center in Redding is called the Sierra Pacific Regional Cancer Center

August 21, 2024 | actionnewsnow.com

Sierra Space eyes IPO market as it braces for a 'profound industrial revolution' in space

April 11, 2024 | msn.com

Sierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'

April 11, 2024 | aol.com

Used 2021 GMC Sierra 2500 trucks for sale near me

April 5, 2024 | cars.com

Anemia of Inflammation

March 26, 2024 | nejm.org

Sierra Oncology Inc.

February 21, 2024 | thestreet.com

Sierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]

February 15, 2024 | prokerala.com

2014 GMC Sierra 1500 specs & colors

February 6, 2024 | cars.com

Used 2014 GMC Sierra 1500 Denali trucks for sale near me

January 5, 2024 | cars.com

2017 GMC Sierra 1500

December 17, 2023 | motortrend.com

Safety in Radiation Oncology (SAFRON)

December 16, 2023 | iaea.org

2024 GMC Sierra 2500HD

November 24, 2023 | driving.ca

Sierra deputies believe bear mauled woman after she died

November 20, 2023 | kcra.com

Sierra Coupon for October

November 9, 2023 | time.com

Compare 6 trims on the 2021 GMC Sierra 1500

October 31, 2023 | cars.com

Clario presents a three-part webinar series on oncology trial solutions

October 31, 2023 | galvnews.com

FDA approves GSK's unique myelofibrosis treatment Ojjaara

September 18, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRA, LEGN, NUVL, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$33.64 +0.18 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$33.51 -0.13 (-0.39%)

As of 04:44 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Legend Biotech NASDAQ:LEGN

$28.75 -0.22 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$28.90 +0.15 (+0.50%)

As of 07:22 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Nuvalent NASDAQ:NUVL

$73.63 -1.13 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$74.58 +0.95 (+1.30%)

As of 04:29 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time